{"id":32520,"date":"2025-04-30T09:00:14","date_gmt":"2025-04-30T07:00:14","guid":{"rendered":"https:\/\/immunostep.com\/?p=32520"},"modified":"2025-04-30T09:03:26","modified_gmt":"2025-04-30T07:03:26","slug":"expansion-of-car-t-therapy-beyond-haematological-malignancies","status":"publish","type":"post","link":"https:\/\/immunostep.com\/es\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/","title":{"rendered":"Expansion of CAR-T therapy: Beyond haematological malignancies"},"content":{"rendered":"<p><a href=\"https:\/\/immunostep.com\/immunology\/car-t\/\">CAR-T therapy<\/a> has revolutionised the treatment of certain haematological cancers, such as acute lymphoblastic leukaemia and B-cell lymphoma. However, recent advances have allowed its application to be expanded to solid tumours and autoimmune diseases, ushering in a new era in personalised immunotherapy.<\/p>\n<p><strong>CAR-T in solid tumours: overcoming barriers <\/strong><\/p>\n<p>Unlike haematological cancers, solid tumours present additional challenges for CAR-T therapy. These include antigenic heterogeneity, immunosuppression of the tumour microenvironment and the difficulty of infiltration of CAR-T cells into the tumour. To overcome these barriers, strategies have been developed such as:<\/p>\n<p><strong>-New target antigens. <\/strong>identification of solid tumour-specific antigens, such as HER2, GD2 and EGFRVIII.<\/p>\n<p><strong>-CAR design modifications. <\/strong>Development of second- and third-generation CARs with multiple co-stimulators to improve lymphocyte persistence and efficacy.<\/p>\n<p><strong>-Use of cytokine receptor-modified T cells.<\/strong> Increased resistance to tumour immunosuppression through the expression of receptors that favour CAR-T lymphocyte proliferation and activation.<\/p>\n<p><strong>-Combination therapies:<\/strong> Synergy with immune checkpoint inhibitors and other targeted therapies to enhance the anti-tumour response.<\/p>\n<p>These advances have allowed CAR-T therapies for solid tumours to begin to demonstrate efficacy in preclinical studies and early clinical trials.<\/p>\n<p><strong>Biomarkers predictive of CAR-T response<\/strong><\/p>\n<p>CAR-T therapy is not equally effective in all patients, so the identification of predictive biomarkers of response is key to its personalisation. Some of the biomarkers under investigation include<\/p>\n<p><strong>-Tumour antigen expression.<\/strong> A high level of target antigen expression (such as CD19 or BCMA) correlates with a better therapeutic response.<\/p>\n<p><strong>-Patient immune profile. <\/strong>The proportion of regulatory T lymphocytes (Tregs) and the functionality of CAR-T cells prior to treatment can predict the success of therapy.<\/p>\n<p><strong>-Genetic and epigenetic factors.<\/strong> Variants in genes related to immune activation may influence the efficacy of CAR-T therapy.<\/p>\n<p>The use of these predictive biomarkers will allow for better patient selection and optimisation of treatment strategies, improving the efficacy of CAR-T therapy.<\/p>\n<p><strong>Reducing Adverse Effects in CAR-T Therapy<\/strong><\/p>\n<p>Despite its efficacy, CAR-T therapy can induce serious adverse effects, such as <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6003181\/\">cytokine release syndrome (CRS)<\/a> and immune cell-associated neurotoxicity (ICANS). To mitigate these risks, strategies have been developed such as:<\/p>\n<p>Use of IL-6 inhibitors (Tocilizumab): drugs such as tocilizumab have demonstrated efficacy in the management of moderate to severe CRS.<\/p>\n<p>Modulation of CAR design: Incorporation of \u201csafety switches\u201d in CAR-T lymphocytes that allow their elimination in case of severe adverse reactions.<\/p>\n<p>Stepwise administration: Fractionated dosing strategies to reduce toxicity without compromising efficacy.<\/p>\n<p>Researchers are evaluating experimental therapies with anakinra and other immunomodulators to block IL-1 and other inflammatory mediators, preventing neurotoxicity. They continue refining these approaches to maximize the safety and tolerability of CAR-T therapy, broadening its clinical application to a greater number of patients.<\/p>\n<p><strong>Conclusions<\/strong><\/p>\n<p>CAR-T therapy is rapidly evolving beyond its initial application in hematological malignancies. Its potential in solid tumors and autoimmune diseases represents a significant advance in personalized medicine. Optimization of predictive biomarkers and strategies to minimize adverse effects will be key to its wider implementation. As research progresses, CAR-T could establish itself as one of the most promising therapies of the 21st century, transforming the treatment of complex diseases with unprecedented precision.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAR-T therapy has revolutionised the treatment of certain haematological cancers, such as acute lymphoblastic leukaemia and B-cell lymphoma. However, recent advances have allowed its application to be expanded to solid tumours and autoimmune diseases, ushering in a new era in personalised immunotherapy. CAR-T in solid tumours: overcoming barriers Unlike haematological cancers, solid tumours present additional [&hellip;]<\/p>\n","protected":false},"author":225,"featured_media":32523,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[2033],"tags":[2031,2154,2117,2160,2218,2159,2215],"class_list":["post-32520","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-immunology","tag-car-t","tag-immune-cells","tag-immunology","tag-immunotherapies","tag-oncology","tag-therapy","tag-treatments"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Expansion of CAR-T therapy: Beyond haematological malignancies | Immunostep Biotech<\/title>\n<meta name=\"description\" content=\"At Immunostep we have been innovating since 2001 to develop comprehensive products that contribute to improve.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Expansion of CAR-T therapy: Beyond haematological malignancies | Immunostep Biotech\" \/>\n<meta property=\"og:description\" content=\"At Immunostep we have been innovating since 2001 to develop comprehensive products that contribute to improve.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/\" \/>\n<meta property=\"og:site_name\" content=\"Immunostep Biotech\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/immunostepsl\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-30T07:00:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-30T07:03:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/03\/celulas-cart-1-e1745996506291.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"901\" \/>\n\t<meta property=\"og:image:height\" content=\"528\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"\u00c1ngela Cabestrero\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Immunostep\" \/>\n<meta name=\"twitter:site\" content=\"@Immunostep\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c1ngela Cabestrero\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/\"},\"author\":{\"name\":\"\u00c1ngela Cabestrero\",\"@id\":\"https:\/\/immunostep.com\/#\/schema\/person\/6f7086a7900eb41588a2465bcae5f427\"},\"headline\":\"Expansion of CAR-T therapy: Beyond haematological malignancies\",\"datePublished\":\"2025-04-30T07:00:14+00:00\",\"dateModified\":\"2025-04-30T07:03:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/\"},\"wordCount\":513,\"publisher\":{\"@id\":\"https:\/\/immunostep.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/03\/celulas-cart-1-e1745996506291.webp\",\"keywords\":[\"CAR T\",\"immune cells\",\"immunology\",\"immunotherapies\",\"oncology\",\"therapy\",\"treatments\"],\"articleSection\":[\"Immunology\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/\",\"url\":\"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/\",\"name\":\"Expansion of CAR-T therapy: Beyond haematological malignancies | Immunostep Biotech\",\"isPartOf\":{\"@id\":\"https:\/\/immunostep.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/03\/celulas-cart-1-e1745996506291.webp\",\"datePublished\":\"2025-04-30T07:00:14+00:00\",\"dateModified\":\"2025-04-30T07:03:26+00:00\",\"description\":\"At Immunostep we have been innovating since 2001 to develop comprehensive products that contribute to improve.\",\"breadcrumb\":{\"@id\":\"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/#primaryimage\",\"url\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/03\/celulas-cart-1-e1745996506291.webp\",\"contentUrl\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/03\/celulas-cart-1-e1745996506291.webp\",\"width\":901,\"height\":528},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/immunostep.com\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Expansion of CAR-T therapy: Beyond haematological malignancies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/immunostep.com\/#website\",\"url\":\"https:\/\/immunostep.com\/\",\"name\":\"Immunostep Biotech\",\"description\":\"Innovating to deliver high-performance technology for Research and Diagnosis\",\"publisher\":{\"@id\":\"https:\/\/immunostep.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/immunostep.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/immunostep.com\/#organization\",\"name\":\"Immunostep Biotech\",\"url\":\"https:\/\/immunostep.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/immunostep.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2021\/10\/logo-web-color.png\",\"contentUrl\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2021\/10\/logo-web-color.png\",\"width\":1299,\"height\":591,\"caption\":\"Immunostep Biotech\"},\"image\":{\"@id\":\"https:\/\/immunostep.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/immunostepsl\/\",\"https:\/\/x.com\/Immunostep\",\"https:\/\/www.linkedin.com\/company\/immunostepsl\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/immunostep.com\/#\/schema\/person\/6f7086a7900eb41588a2465bcae5f427\",\"name\":\"\u00c1ngela Cabestrero\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/immunostep.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/378033e78b9b0300f6f50aeac830c5cf?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/378033e78b9b0300f6f50aeac830c5cf?s=96&d=mm&r=g\",\"caption\":\"\u00c1ngela Cabestrero\"},\"url\":\"https:\/\/immunostep.com\/es\/author\/acabestrero\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Expansion of CAR-T therapy: Beyond haematological malignancies | Immunostep Biotech","description":"At Immunostep we have been innovating since 2001 to develop comprehensive products that contribute to improve.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/","og_locale":"es_ES","og_type":"article","og_title":"Expansion of CAR-T therapy: Beyond haematological malignancies | Immunostep Biotech","og_description":"At Immunostep we have been innovating since 2001 to develop comprehensive products that contribute to improve.","og_url":"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/","og_site_name":"Immunostep Biotech","article_publisher":"https:\/\/www.facebook.com\/immunostepsl\/","article_published_time":"2025-04-30T07:00:14+00:00","article_modified_time":"2025-04-30T07:03:26+00:00","og_image":[{"width":901,"height":528,"url":"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/03\/celulas-cart-1-e1745996506291.webp","type":"image\/webp"}],"author":"\u00c1ngela Cabestrero","twitter_card":"summary_large_image","twitter_creator":"@Immunostep","twitter_site":"@Immunostep","twitter_misc":{"Escrito por":"\u00c1ngela Cabestrero","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/#article","isPartOf":{"@id":"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/"},"author":{"name":"\u00c1ngela Cabestrero","@id":"https:\/\/immunostep.com\/#\/schema\/person\/6f7086a7900eb41588a2465bcae5f427"},"headline":"Expansion of CAR-T therapy: Beyond haematological malignancies","datePublished":"2025-04-30T07:00:14+00:00","dateModified":"2025-04-30T07:03:26+00:00","mainEntityOfPage":{"@id":"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/"},"wordCount":513,"publisher":{"@id":"https:\/\/immunostep.com\/#organization"},"image":{"@id":"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/#primaryimage"},"thumbnailUrl":"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/03\/celulas-cart-1-e1745996506291.webp","keywords":["CAR T","immune cells","immunology","immunotherapies","oncology","therapy","treatments"],"articleSection":["Immunology"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/","url":"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/","name":"Expansion of CAR-T therapy: Beyond haematological malignancies | Immunostep Biotech","isPartOf":{"@id":"https:\/\/immunostep.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/#primaryimage"},"image":{"@id":"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/#primaryimage"},"thumbnailUrl":"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/03\/celulas-cart-1-e1745996506291.webp","datePublished":"2025-04-30T07:00:14+00:00","dateModified":"2025-04-30T07:03:26+00:00","description":"At Immunostep we have been innovating since 2001 to develop comprehensive products that contribute to improve.","breadcrumb":{"@id":"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/#primaryimage","url":"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/03\/celulas-cart-1-e1745996506291.webp","contentUrl":"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/03\/celulas-cart-1-e1745996506291.webp","width":901,"height":528},{"@type":"BreadcrumbList","@id":"https:\/\/immunostep.com\/2025\/04\/30\/expansion-of-car-t-therapy-beyond-haematological-malignancies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/immunostep.com\/es\/"},{"@type":"ListItem","position":2,"name":"Expansion of CAR-T therapy: Beyond haematological malignancies"}]},{"@type":"WebSite","@id":"https:\/\/immunostep.com\/#website","url":"https:\/\/immunostep.com\/","name":"Immunostep Biotech","description":"Innovating to deliver high-performance technology for Research and Diagnosis","publisher":{"@id":"https:\/\/immunostep.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/immunostep.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/immunostep.com\/#organization","name":"Immunostep Biotech","url":"https:\/\/immunostep.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/immunostep.com\/#\/schema\/logo\/image\/","url":"https:\/\/immunostep.com\/wp-content\/uploads\/2021\/10\/logo-web-color.png","contentUrl":"https:\/\/immunostep.com\/wp-content\/uploads\/2021\/10\/logo-web-color.png","width":1299,"height":591,"caption":"Immunostep Biotech"},"image":{"@id":"https:\/\/immunostep.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/immunostepsl\/","https:\/\/x.com\/Immunostep","https:\/\/www.linkedin.com\/company\/immunostepsl\/"]},{"@type":"Person","@id":"https:\/\/immunostep.com\/#\/schema\/person\/6f7086a7900eb41588a2465bcae5f427","name":"\u00c1ngela Cabestrero","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/immunostep.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/378033e78b9b0300f6f50aeac830c5cf?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/378033e78b9b0300f6f50aeac830c5cf?s=96&d=mm&r=g","caption":"\u00c1ngela Cabestrero"},"url":"https:\/\/immunostep.com\/es\/author\/acabestrero\/"}]}},"_links":{"self":[{"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/posts\/32520"}],"collection":[{"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/users\/225"}],"replies":[{"embeddable":true,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/comments?post=32520"}],"version-history":[{"count":1,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/posts\/32520\/revisions"}],"predecessor-version":[{"id":32525,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/posts\/32520\/revisions\/32525"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/media\/32523"}],"wp:attachment":[{"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/media?parent=32520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/categories?post=32520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/tags?post=32520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}